Skip to main content
Article thumbnail
Location of Repository

B7-H1 Blockade Increases Survival of Dysfunctional CD8+ T Cells and Confers Protection against Leishmania donovani Infections

By Trupti Joshi, Susana Rodriguez, Vladimir Perovic, Ian A. Cockburn and Simona Stäger

Abstract

Experimental visceral leishmaniasis (VL) represents an exquisite model to study CD8+ T cell responses in a context of chronic inflammation and antigen persistence, since it is characterized by chronic infection in the spleen and CD8+ T cells are required for the development of protective immunity. However, antigen-specific CD8+ T cell responses in VL have so far not been studied, due to the absence of any defined Leishmania-specific CD8+ T cell epitopes. In this study, transgenic Leishmania donovani parasites expressing ovalbumin were used to characterize the development, function, and fate of Leishmania-specific CD8+ T cell responses. Here we show that L. donovani parasites evade CD8+ T cell responses by limiting their expansion and inducing functional exhaustion and cell death. Dysfunctional CD8+ T cells could be partially rescued by in vivo B7-H1 blockade, which increased CD8+ T cell survival but failed to restore cytokine production. Nevertheless, B7-H1 blockade significantly reduced the splenic parasite burden. These findings could be exploited for the design of new strategies for immunotherapeutic interventions against VL

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2674929
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2006). Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen.
    2. (1992). Altered course of visceral leishmaniasis in mice expressing transgenic I-E molecules.
    3. (2003). B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression.
    4. (2007). B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B.
    5. Badovinac VP (2008) Shaping and reshaping CD8+ T cell memory.
    6. (2003). Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.
    7. (2008). Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model.
    8. (2003). Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
    9. (2005). CD69 is an immunoregulatory molecule induced following activation.
    10. (2007). CD8 T cell dysfunction during chronic viral infection. Curr Opin Immunol 19: 408–415.
    11. (2002). CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major.
    12. (2006). Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction.
    13. (2004). Co-inhibitory molecules of the B7-CD28 family in the control of T cell immunity.
    14. (1998). Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection.
    15. (2001). Cross-presentation, dendritic cells, tolerance and immunity.
    16. (2003). Cutting edge: dysfunctional CD8+ T cells reside in nonlymphoid tissues during chronic Trypanosoma cruzi infection.
    17. (2005). Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin.
    18. (2008). Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection.
    19. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
    20. (2002). Estimating the precursor frequency of naive antigen-specific CD8 T cells.
    21. (1998). Evolution of a complex T cell receptor repertoire during primary and recall bacterial infection.
    22. (2000). Fibroblasts as host cells in latent leishmaniosis.
    23. (2008). Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates.
    24. (2004). Generation, specificity, and function of CD8+ T cells in Trypanosoma cruzi infection.
    25. (2007). Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13.
    26. (2001). IL-10 mediates susceptibility to Leishmania donovani infection.
    27. (2006). Immune resistance orchestrated by the tumor microenvironment.
    28. (2000). Immunization with a recombinant stageregulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
    29. (2007). Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses.
    30. (2008). Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis.
    31. (2004). Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani.
    32. (2007). Impaired NFAT nuclear translocation results in split exhaustion of virus-specific CD8+ T cell functions during chronic viral infection.
    33. (1993). In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin10 and interferon-gamma.
    34. (2008). In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies.
    35. (2007). Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor.
    36. (2007). Initial T cell receptor transgenic cell precursor frequency dictates critical aspects of the CD8(+) T cell response to infection.
    37. (2007). Interaction between B7-H1 and PD-1 determines initiation and reversal of T cell anergy.
    38. (1993). Interleukin 10 production correlates with pathology in human Leishmania donovani infections.
    39. (2002). Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.
    40. (2003). Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis.
    41. KaechSM,WherryEJ,AhmedR(2002)EffectorandmemoryTcelldifferentiation: implications for vaccine development.
    42. (2006). Leishmania antigens are presented to CD8+ T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo.
    43. (2005). Leishmania major modulates chemokine and chemokine receptor expression by dendritic cells and affects their migratory capacity.
    44. (2003). Lineage relationship and protective immunity of memory CD8 T cell subsets.
    45. (1998). Massive expansion of antigen-specific CD8+ T cells during an acute virus infection.
    46. (2007). Molecular signature of CD8+ T cell exhaustion during chronic viral infection.
    47. (2003). Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T cell responses.
    48. (2008). Pathogen-imposed skewing of mouse chemokine and cytokine expression at the infected tissue site.
    49. (2003). Perforin and gamma interferon are critical CD8+ T cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection.
    50. (2008). Posttranscriptional regulation of il10 gene expression allows natural killer cells to express immunoregulatory function.
    51. (2002). Programmed contraction of CD8(+) T cells after infection.
    52. (2006). Quantification of repertoire diversity of influenza-specific epitopes with predominant public or private TCR usage.
    53. (1996). Regulation of the expression of nitric oxide synthase and leishmanicidal activity by glycoconjugates of Leishmania lipophosphoglycan in murine macrophages.
    54. (2007). Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells.
    55. (2006). Restoring function in exhausted CD8 T cells during chronic viral infection.
    56. (1988). Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis.
    57. (2007). Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.
    58. (2003). Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.
    59. (2000). Size estimate of the alpha beta TCR repertoire of naive mouse splenocytes.
    60. (2007). Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis.
    61. (2008). Stable CD8+ T cell memory during persistent Trypanosoma cruzi infection.
    62. (2005). Subversion of host cell signalling by the protozoan parasite Leishmania.
    63. (2001). T cell death and memory.
    64. (2008). T Cells from Leishmania majorsusceptible BALB/c mice have a defect in efficiently up-regulating CXCR3 upon activation.
    65. (2005). The B7 family revisited.
    66. (2004). The immunopathology of experimental visceral leishmaniasis.
    67. (2008). Tumor-induced immune suppression of in vivo effector T cell priming is mediated by the B7-H1/ PD-1 axis and transforming growth factor beta.
    68. (2002). Tumorassociated B7-H1 promotes T cell apoptosis: a potential mechanism of immune evasion.
    69. (2006). Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity.
    70. (1997). Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    71. (1998). Viral immune evasion due to persistence of activated T cells without effector function.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.